Introduction
In general, fetal arrhythmias are detected during the second or third trimester routine obstetric ultrasound and occur in up to 2% of all pregnancies [1] . Most fetal arrhythmias are benign and transient; however, some of them, such as sustained tachycardia (up to 200 beats per minute [bpm] ), may result in low cardiac output, fetal hydrops and fetal demise. Supraventricular tachycardia (SVT) is the most common type of tachycardia and a frequent cause of non-immune hydrops [2] .
Cardiac ultrasound/echocardiography can be used to assess the fetal cardiac rhythm, enabling the differential diagnosis of the majority of tachyarrhythmias. The ventriculoatrial (VA) and atrioventricular (AV) time intervals should be measured by M-mode and Doppler ultrasound [3] . The AV and VA intervals are mechanical analogs of the PR and RP electric intervals of the ECG. The short VA type of SVT is more common than long VA sinus tachycardia (ST), which is more difficult to diagnose and treat in utero. Ectopic atrial tachycardia and permanent junctional reciprocating tachycardia are long VA types of SVT. Cardiac ultrasound provides a way to assess the hemodynamic consequences of the tachyarrhythmias, aiding the detailed analysis of the fetal cardiac anatomy. Ebstein's anomaly, cardiac tumors, and myocarditis should be excluded.
(>200 bpm) noted in a routine obstetric ultrasound performed at 11 weeks of gestation. There was no history of infectious diseases, thyrotoxicosis, or consumption of any drugs. The patient was diabetic and insulin dependent.
The transvaginal fetal echocardiogram confirmed the tachycardia with fetal heart rate (HR) ranging from 215 to 239 bpm with 1:1 AV relationship and long VA interval (VA/AV ratio = 3.0; VA interval time = 223 msec) (fig 1) . The fetal echocardiogram showed normal cardiac anatomy and no signs of hydrops.
Maternal electrocardiogram (ECG) and renal function results were normal and oral digoxin was started at 2.0 mg/ day, reduced every 24 hrs to 1.5 mg and 1.0 mg/day. Because of the persistence of fetal SVT, sotalol (320 mg/ day) was added to digoxin (0.25 mg twice daily). Sotalol was suspended due to the prolongation of the maternal QT interval and the patient was discharged with digoxin. Subsequently, as the fetus maintained the SVT and maternal ECG QT interval was normalized, sotalol was once again added (240 mg/day) to digoxin. The conversion to sinus rhythm was achieved by weeks 20 onwards and the fetal HR remained stable until 39 weeks of gestation. The male baby was born healthy, weighing 3675 g, with Apgar scores of 9 and 10 at 1 and 5 min, respectively. The neonatal electrocardiogram and echocardiogram were normal and he was discharged with propranolol therapy regimen.
Discussions
Tachyarrhythmias are divided into three categories: ST, SVT (atrial flutter, atrial ectopic tachycardia, and conduction type tachycardias), and ventricular tachycardia (VT). SVT is the most common type of tachycardia with VT as the rarest type [1, 4] .
In general, arrhythmias are detected from the second trimester of pregnancy onwards being more frequently after 25 weeks of gestation [5] . Rarely, SVT has early onset and has been diagnosed as early as 13 weeks of gestation [6] .
Although fetal magnetocardiography is an effective and promising non-invasive technique to assess fetal cardiac electrical impulses, cardiac Doppler ultrasound is currently the most commonly used tool in a clinical setting [7] . The assessment of the relationships between atrial and ventricular contractions is crucial for an accurate diagnosis of fetal arrhythmias by using M-mode and Doppler ultrasound (fig 2) . The M-mode technique can be used to obtain better quality recordings as early as the first trimester, especially in cases of unfavorable fetal position or increased body mass index in the mother.
In ST, atrial and ventricular rates are similar (1:1 AV relationship), and the HR is more variable and lower (at or below 200 bpm) than in SVT. Re-entrant SVT is the most common type of SVT, where the HR usually ranges between 220 and 300 bpm, with 1:1 AV and short A-V time interval. The anatomical substrate of re-entrant SVT is the presence of an accessory electrical conduction pathway. As the retrograde conduction is fast, the atrium is excited shortly after the ventricle, which generates a short VA time interval on Doppler or M-mode ultrasound (VA < AV) with a fast HR. SVT with longer VA interval (VA > AV) includes atrial ectopic tachycardia and persistent junctional reciprocating tachycardia (PJRT) [8] . PJRT is a rare type of re-entrant SVT in which the retrograde pathway has a slow conduction leading to a characteristic long AV interval with 1:1 AV. In atrial ectopic tachycardia, the mechanism is related to an atrial automatic focus with 1:1 AV relationship and variable HR (ranging from 160 to 250 bpm). Because of the longer AV interval, PJRT or atrial tachycardia are the possible types of SVT considered in this case report.
Another type of SVT is junctional tachycardia (JET) which is extremely rare in utero,. It is caused by an automatic ectopic focus in the AV junction in which the A wave is superimposed on the V wave. Fetal JET and AF have been reported to be related to Anti-Ro (SSA) and La (SSB) isoimmunization. AF is a type of SVT caused by an intra-atrial re-entry circuit with atrial rate higher than ventricular rate (atrial rate ranging from 350 to 500 bpm), usually with a 2:1 ratio. It is observed only in the third trimester of pregnancy [4, 5] .
For treatment in utero, antiarrhythmic medications are recommended for all sustained SVT, VT, intermittent SVT with hydrops, and VT with HR >200 bpm. The only exception is for near term fetuses with SVT/VT. Antiarrhythmic medications are used transplacentally in the pregnant woman (given orally or intravenously) or in the fetus. Currently, digoxin is still the first-line therapy in many centers to treat fetuses with fetal SVT mainly in short AV SVT. In other centers, flecainide or sotalol have been used as first-line therapy [5] .
A recent systematic review and meta-analysis demonstrated that flecainide is more effective than digoxin in treating SVT with fewer adverse effects [9] . In refractory SVT, amiodarone has been used as second-or third-line therapy alone or in combination with digoxin. In the case presented, the initial therapy was digoxin because flecainide was unavailable in our country. Subsequently, as amiodarone is contraindicated during the first trimester because of the side effect of fetal/neonatal hypothyroidism, a combination therapy with sotalol and digoxin was used to treat SVT in the reported case, with a successful outcome. Interestingly, postnatal recurrence of SVT during the first year of life has been described (10-20% of SVT) [10] . Therefore, the drug regimen was continued as a prophylactic to prevent recurrence of SVT in this case.
In summary, sustained SVT is extremely rare during the first trimester of pregnancy. The goal of treatment in utero is the conversion to sinus rhythm or reduction of the ventricular rate to tolerable levels thereby preventing or even reversing fetal hydrops.
